Laurel Wealth Advisors (North Carolina)’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-150	Closed	-$8K	–	706
2021 Q4	$8K	Hold	150	–	–	﹤0.01%	438
2021 Q3	$6K	Hold	150	–	–	﹤0.01%	464
2021 Q2	$6K	Hold	150	–	–	﹤0.01%	532
2021 Q1	$5K	Hold	150	–	–	﹤0.01%	515
2020 Q4	$5K	Hold	150	–	–	﹤0.01%	490
2020 Q3	$4K	Hold	150	–	–	﹤0.01%	449
2020 Q2	$4K	Hold	150	–	–	﹤0.01%	444
2020 Q1	$2K	Hold	150	–	–	﹤0.01%	481
2019 Q4	$5K	Hold	150	–	–	﹤0.01%	446
2019 Q3	$1K	Hold	150	–	–	﹤0.01%	505
2019 Q2	$2K	Hold	150	–	–	﹤0.01%	490
2019 Q1	$2K	Hold	150	–	–	﹤0.01%	465
2018 Q4	$2K	Buy	+150	New	+$2.42K	﹤0.01%	470

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s ITCI Position: Q1 2022 in Review

Laurel Wealth Advisors (North Carolina) sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2022, closing a stake of 150 shares — an estimated $8K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in ITCI in Q4 2018 and held it in 13 quarters. The position peaked at $8K in Q4 2021. 241 funds tracked by Wall St. Rank hold ITCI as of Q1 2022.

Laurel Wealth Advisors (North Carolina) reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2022 after selling out during the quarter.
Laurel Wealth Advisors (North Carolina) sold 150 Intra-Cellular Therapies Inc. shares in Q1 2022, an estimated $8K.
Laurel Wealth Advisors (North Carolina) first reported a position in Intra-Cellular Therapies Inc. in Q4 2018 and held it in 13 quarters.
Laurel Wealth Advisors (North Carolina)'s Intra-Cellular Therapies Inc. position peaked at $8K in Q4 2021.
241 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2022.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q1 2022, filed 2 May 2022.